{"id":"insulin-glargine-300-u-ml","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201497","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin glargine is a recombinant human insulin analog modified to have an extended duration of action (up to 24 hours). It binds to the insulin receptor on target tissues including muscle, fat, and liver, facilitating glucose transport into cells and promoting glycogen synthesis while inhibiting gluconeogenesis. The 300 U/ml formulation is a higher concentration allowing for smaller injection volumes.","oneSentence":"Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:10.031Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06671587","phase":"PHASE4","title":"iGlarLixi CGM Study in Chinese T2D Individuals After OADs","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-12-10","conditions":"Type 2 Diabetes (T2D)","enrollment":678},{"nctId":"NCT05002933","phase":"PHASE4","title":"A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-05-20","conditions":"Type 2 Diabetes Mellitus","enrollment":570},{"nctId":"NCT04980027","phase":"PHASE4","title":"Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-06-07","conditions":"Type 2 Diabetes Mellitus","enrollment":228},{"nctId":"NCT05552859","phase":"PHASE4","title":"Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment","status":"TERMINATED","sponsor":"Sanofi","startDate":"2022-12-05","conditions":"Type 2 Diabetes Mellitus, Renal Impairment","enrollment":62},{"nctId":"NCT05780151","phase":"PHASE4","title":"Remote And Decentralised Innovative Approaches to Clinical Trials (RADIAL)","status":"COMPLETED","sponsor":"Mira Zuidgeest","startDate":"2023-07-10","conditions":"Diabetes Mellitus, Type 2","enrollment":107},{"nctId":"NCT05607160","phase":"","title":"A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-10-05","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":82},{"nctId":"NCT05457933","phase":"PHASE4","title":"Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2022-07-29","conditions":"Type2diabetes, Coronary Artery Disease","enrollment":250},{"nctId":"NCT04075513","phase":"PHASE4","title":"Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-10-09","conditions":"Type 1 Diabetes Mellitus","enrollment":343},{"nctId":"NCT05109520","phase":"","title":"Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL","status":"COMPLETED","sponsor":"prof dr Pieter Gillard","startDate":"2021-09-08","conditions":"Type 1 Diabetes","enrollment":867},{"nctId":"NCT03760991","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-12-18","conditions":"Type 2 Diabetes Mellitus","enrollment":372},{"nctId":"NCT03406000","phase":"PHASE4","title":"Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-01-22","conditions":"Type I Diabetes Mellitus","enrollment":170},{"nctId":"NCT03260868","phase":"PHASE4","title":"Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)","status":"TERMINATED","sponsor":"Sanofi","startDate":"2017-09-19","conditions":"Type 1 Diabetes Mellitus","enrollment":15},{"nctId":"NCT02688933","phase":"PHASE4","title":"A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-05","conditions":"Type 1 Diabetes Mellitus","enrollment":638},{"nctId":"NCT02735044","phase":"PHASE3","title":"Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-04-14","conditions":"Type 1 Diabetes Mellitus","enrollment":463},{"nctId":"NCT01499082","phase":"PHASE3","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-12","conditions":"Type 2 Diabetes Mellitus","enrollment":807},{"nctId":"NCT01499095","phase":"PHASE3","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-12","conditions":"Type 2 Diabetes Mellitus","enrollment":811},{"nctId":"NCT05155917","phase":"PHASE2","title":"Concurrent Subcutaneous Basal Insulin and Intravenous Insulin Pump in Hyperglycemic Crisis Patients Under Critical Care","status":"UNKNOWN","sponsor":"Changhua Christian Hospital","startDate":"2022-03-01","conditions":"Hyperglycaemic Crisis in Diabetes Mellitus, Diabetic Ketoacidosis, Hyperglycaemic Hyperosmolar Nonketotic Syndrome","enrollment":70},{"nctId":"NCT03078478","phase":"PHASE3","title":"A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-03-13","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1609},{"nctId":"NCT02320721","phase":"PHASE3","title":"Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":1014},{"nctId":"NCT02451137","phase":"PHASE4","title":"A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-06-16","conditions":"Diabetes Mellitus, Type 2","enrollment":3304},{"nctId":"NCT02536859","phase":"PHASE1","title":"Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-08-31","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":60},{"nctId":"NCT02738151","phase":"PHASE4","title":"Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-19","conditions":"Diabetes Mellitus, Type 2","enrollment":929},{"nctId":"NCT02443402","phase":"PHASE4","title":"Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-01","conditions":"Coronary Artery Disease","enrollment":68},{"nctId":"NCT01683266","phase":"PHASE3","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-09","conditions":"Type 1 Diabetes Mellitus","enrollment":549},{"nctId":"NCT01676220","phase":"PHASE3","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-08","conditions":"Type 2 Diabetes Mellitus","enrollment":878},{"nctId":"NCT01658579","phase":"PHASE2","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-08","conditions":"Type 1 Diabetes Mellitus","enrollment":59},{"nctId":"NCT01226043","phase":"PHASE4","title":"Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-10","conditions":"Diabetes Mellitus, Type 2","enrollment":405},{"nctId":"NCT00993473","phase":"PHASE3","title":"6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-10","conditions":"Type 1 Diabetes Mellitus","enrollment":125}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":190,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HOE901 Toujeo","Toujeo","HOE901-U300"],"phase":"marketed","status":"active","brandName":"Insulin glargine 300 U/ml","genericName":"Insulin glargine 300 U/ml","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}